Verified Beauty Data

Data guide / Concentration guide

What percentage of adapalene actually works?

0.1% is the over-the-counter strength (Differin and its generics) with the deepest clinical trial base — matching tretinoin 0.025% on efficacy while causing far less irritation. 0.3% is reserved for prescription use in moderate-to-severe acne.

OTC evidence-based strength

0.1%

Adapalene comes in exactly two concentrations with clinical backing: 0.1%, the strength sold over the counter in the US since 2016 as Differin, and 0.3%, reserved for prescription use in moderate-to-severe acne, also available in fixed-dose combination with 2.5% benzoyl peroxide. A meta-analysis of five randomized trials (900 patients) found adapalene 0.1% gel matched tretinoin 0.025% gel on lesion reduction, worked faster in week one, and was considerably better tolerated. There is no OTC strength above 0.1% — 0.3% is prescription-only, and there's no published dose-finding evidence supporting an OTC concentration below 0.1%.

Adapalene dossier ↗

02 / 0.1% — the OTC evidence base

Why 0.1%: the strength every major head-to-head trial actually tested

0.1% adapalene gel is the concentration behind essentially every landmark trial establishing adapalene's place in acne treatment. In a 12-week multicenter randomized trial, adapalene 0.1% gel reduced total acne lesions by about 49%, versus 37% for tretinoin 0.025% gel, with cutaneous side effects described as limited. A meta-analysis pooling five randomized trials (900 patients total) confirmed adapalene 0.1% gel had efficacy equivalent to tretinoin 0.025% gel in reducing total lesions, acted more rapidly (a difference significant as early as week one), and delivered considerably better local tolerability. This is also the strength every disclosed adapalene product in our catalog uses — Differin Adapalene Gel, Acne Free Adapalene Gel, and La Roche-Posay Effaclar Adapalene Gel are all 0.1%, reflecting that this is the FDA-approved OTC strength (switched from prescription-only status in 2016), not a range shoppers choose within.

03 / 0.3% — prescription tier, plus BPO combinations

0.3% adapalene and fixed-dose benzoyl peroxide combinations: the prescription step-up

0.3% is the stronger, prescription-only adapalene concentration reserved for moderate-to-severe acne, and it's also formulated in once-daily fixed-dose combination with 2.5% benzoyl peroxide — a pairing with proven efficacy and good tolerability that leverages adapalene's retinoid mechanism alongside benzoyl peroxide's antimicrobial action. A network meta-analysis of topical acne treatments found the benzoyl-peroxide-plus-adapalene combination among the most effective options for self-reported improvement (54% versus 35% for vehicle). Unlike tretinoin, which benzoyl peroxide degrades, adapalene is photochemically and chemically stable enough to be combined with BPO in a single product — a genuine formulation advantage that has nothing to do with which single-agent percentage is 'stronger.'

04 / 0.1% as long-term maintenance

0.1% isn't just for getting clear — it's the studied maintenance dose too

The same 0.1% OTC strength that clears active breakouts is also the concentration studied for keeping skin clear afterward. As maintenance therapy following an initial combination course, adapalene 0.1% gel produced significantly higher maintenance rates than vehicle (75% versus 54%) with lower lesion counts, and was described as safe and well tolerated over the maintenance period. That matters for how to think about the percentage question: 0.1% isn't a 'starter' dose that stops working once acne clears — it's the studied concentration across both the active-treatment and maintenance phases, with 0.3% reserved for cases needing more prescription-strength intervention rather than for long-term upkeep.

05 / Summary

Key takeaways

  1. 0.1% is the OTC evidence-based strength (Differin and its generics) — a meta-analysis of five RCTs (900 patients) found it matched tretinoin 0.025% on efficacy, worked faster, and was considerably better tolerated.
  2. All three disclosed adapalene products in our catalog — Differin Adapalene Gel, Acne Free Adapalene Gel, La Roche-Posay Effaclar Adapalene Gel — use the same 0.1%, the FDA-approved OTC strength since 2016.
  3. 0.3% is prescription-only, reserved for moderate-to-severe acne, and is also formulated in fixed-dose combination with 2.5% benzoyl peroxide — a combination adapalene's stability allows and tretinoin's does not.
  4. 0.1% is also the studied maintenance dose: it kept 75% of patients clear versus 54% on vehicle after an initial treatment course.
  5. There's no published evidence for an OTC adapalene strength below 0.1%, and no evidence that going above 0.1% without a prescription adds benefit — 0.3% is a supervised, prescription-tier step-up, not a stronger version to self-select.

Decision / What to buy

What actually discloses Adapalene's %

Every product below states its Adapalene percentage on the label or product page — ranked cheapest first by price per gram of active.

  1. 01

    Differin

    Adapalene Gel 0.1%

    0.1% Adapalene
    Shop $23.97
  2. 02

    La Roche-Posay

    Effaclar Adapalene Gel 0.1%

    0.1% Adapalene
    Shop $32.99

Affiliate links — we may earn a commission at no extra cost to you. Prices and disclosed % are set by the brand and can change.

06 / Questions

Frequently asked

What percentage of adapalene should I use?
Start with 0.1% — it's the FDA-approved over-the-counter strength (Differin and its generics), and it's the concentration behind the largest body of clinical evidence, including a meta-analysis of five randomized trials (900 patients) showing it matches tretinoin 0.025% on efficacy while being considerably better tolerated. All three disclosed adapalene products in our catalog use this same 0.1%. 12
Is 0.3% adapalene stronger and better than 0.1%?
0.3% is reserved for prescription use in moderate-to-severe acne and is also available in fixed-dose combination with 2.5% benzoyl peroxide, but it isn't simply a 'better' version to self-select — it's a supervised step-up for cases the 0.1% OTC strength doesn't fully address. There's no head-to-head consumer-facing trial in this dossier comparing 0.1% versus 0.3% adapalene alone; the published comparisons are 0.1% adapalene versus tretinoin, not versus adapalene 0.3%. 3
Can I combine adapalene with benzoyl peroxide?
Yes, and it's a well-evidenced combination. Adapalene and benzoyl peroxide have complementary mechanisms (retinoid plus antimicrobial), and a network meta-analysis of topical acne treatments found the combination among the most effective options for self-reported improvement (54% vs 35% for vehicle). Adapalene's chemical stability lets it be combined with benzoyl peroxide in a single fixed-dose product — an advantage tretinoin doesn't have, since benzoyl peroxide degrades tretinoin. 43
Does 0.1% adapalene work for blackheads, or only inflamed pimples?
Both, at the same 0.1% strength. As a comedolytic retinoid it normalizes the follicular plugging behind blackheads and whiteheads while also calming inflammatory papules and pustules, and it reduces sebum buildup — a dual action documented at the OTC 0.1% concentration, not requiring the prescription 0.3% tier. 67
Can I use 0.1% adapalene long-term, or do I need to step up to 0.3%?
Long-term, 0.1% is the studied maintenance dose, not just a starting dose. As maintenance therapy after an initial course, adapalene 0.1% gel kept significantly more people clear than vehicle (75% versus 54%) and was safe and well tolerated over the maintenance period. Stepping up to 0.3% is a decision for moderate-to-severe or treatment-resistant acne, made with a dermatologist — not a default progression from the OTC strength. 5

07 / References

Sources

7 references · verified 2026-07-30
  1. 1
  2. 2
  3. 3

    Adapalene/benzoyl peroxide gel 0.3%/2.5% for acne vulgaris

    Stein Gold L, Baldwin H, Kircik LH, et al · Eur J Dermatol 32(4):391-399 · 2022

  4. 4
  5. 5
  6. 6

    Mechanisms of the comedolytic and anti-inflammatory properties of topical retinoids

    Czernielewski J, Michel S, Bouclier M, et al · J Drugs Dermatol review · 2005

  7. 7